When was Bioloomics founded?

Bioloomics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Bioloomics located?

Bioloomics is headquartered in Boulder, United States. It is registered at 4725 Nautilus Ct. S. Unit 1, Boulder, CO 80301, US.

How many employees does Bioloomics have?

As of Aug 31, 2026, the latest employee count at Bioloomics is 7.

Is Bioloomics a funded company?

Bioloomics is a funded company, having raised a total of $9.95M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 10, 2019.

When was the latest funding round of Bioloomics?

Bioloomics' latest funding was a $***** Seed round on Mar 13, 2023, with participation from 7 investors. Its primary sector is Services for Healthcare Providers. In United States, the Services for Healthcare Providers sector has seen $932M in funding in 2026 to date.

Where does Bioloomics rank among its competitors?

Bioloomics ranks 2nd amongst 11 active competitors, of which 3 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Sarcio, which secured $785K in Jul, 2023.

Who are the top competitors of Bioloomics?

Bioloomics' top competitors include Cimeio Therapeutics, Stem Cells Baby and Sarcio. Among them, Sarcio secured the most recent funding round in July, 2023.

Bioloomics - 2026 Company Profile, Funding & Competitors

Company Details

Website: www.bioloomics.com/
Registered Address: 4725 Nautilus Ct. S. Unit 1, Boulder, CO 80301, US

Key Metrics

Founded Year

2018

Location

Boulder, United States

Stage

Seed

Total Funding

$9.95M in 2 rounds

Latest Funding Round

Seed, Mar 13, 2023, $*****

Investors

Innovation Endeavors & 7 more

Ranked

2^nd among 11 active competitors

Employee Count

7 as on Aug 31, 2026

Similar Companies

Cimeio Therapeutics & 10 more

View Bioloomics' full profile

Bioloomics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
BioLoomics, Inc. CIN: 20231189537 , United States, Active	Feb 22, 2023	-	-	-

Bioloomics has raised a total funding of $9.95M over 2 rounds. Its first funding round was on Jun 10, 2019. Its latest funding round was a Seed round on Mar 13, 2023 for $*****. 7 investors participated in its latest round. Bioloomics has 7 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Bioloomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 13, 2023	2730278	Seed	3548757	9155429	1407349	8685405
Jun 10, 2019	8912939	Seed	3096377	1171079	8006551	4929053

Access funding benchmarks and valuations. Sign up today!

View details of Bioloomics's funding rounds and investors

Bioloomics' employee count trend

Bioloomics has 7 employees as of Aug 26. Here is Bioloomics's employee count trend over the years:

Uncover Bioloomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bioloomics include Cimeio Therapeutics, Stem Cells Baby and Sarcio. Here is the list of Top 10 competitors of Bioloomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cimeio Therapeutics 2020, Basel (Switzerland), Series A	Provider of hematopoietic stem cell transplant and adoptive cell therapy services	$50M	Versant Ventures, BaseLaunch	33/100
2nd	Bioloomics 2018, Boulder (United States), Seed	Limited information available	$9.95M	Hummingbird Ventures, Innovation Endeavors ... & 6 others	32/100
3rd	Stem Cells Baby 2000, West Drayton (United Kingdom), Early Stage	Operator of a stem cell storage bank for future use	$600K	-	23/100
4th	Sarcio 2017, Minneapolis (United States), Seed	Developer of an allogenic, iPSC-derived cartilage cell therapy for osteoarthritis. This therapy aims to restore hyaline cartilage and reduce inflammation, delaying or preventing the need for joint replacement surgery. The treatment is designed to be off-the-shelf and injectable, providing a less invasive alternative to traditional methods. The company's approach focuses on reaching patients early to improve joint function and alleviate pain. The technology utilizes high-quality hyaline cartilage cells generated through a proprietary method to achieve cartilage restoration, regeneration, and repair.	$785K	-	20/100
5th	Store a Cell 2012, Mexico City (Mexico), Funding Raised	Provider of mesenchymal stem cells storage services	-	-	19/100
6th	CSG Bio 2000, Scottsdale (United States), Unfunded	Provider of stem cell collection and long term storage services	-	-	16/100
7th	Korean Skin Stem Cell Center Switzerland, Unfunded	Provider of stem cell therapies for tissue regeneration and aesthetic applications	-	-	16/100
8th	ViviCells International 2018, Evanston (United States), Unfunded	Healthcare company focused on the collection, storage, and processing of stem cells	-	-	16/100
9th	Integrated-Health-Systems Unfunded	Provider of regenerative medicine therapies including gene, stem cell, and exosomes	-	-	16/100
10th	Regenerative Care Network 2017, Austin (United States), Deadpooled	Provides access to regenerative cell therapy and allows texas doctors to administer stem cell therapy legally	-	-	16/100